SPRK

$VLN

$MLYS Trading like someone out there got some info!

$MLYS added a few 26.5s

$RLMD Mizuho analyst Uy Ear raised the firm's price target on Relmada Therapeutics to $19 from $10 and keeps an Outperform rating on the shares. The company reported "productive" Q4 results, marked by continued execution, the analyst tells investors in a research note. The firm says the better than expected 12-months durability data strengthens its conviction in NDV-01's "best-in-class potential" and market opportunity.

$OMER Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $156.8 million, or $2.70 per share, in the prior year. Fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. The fourth quarter also includes a $136.0 million non-cash charge associated with the mark-to-market adjustment on the embedded derivatives related to our 2029 Notes and Term Loan. Excluding the non-cash charge associated with the embedded derivatives, non-GAAP adjusted net income for the three months and year ended December 31, 2025 was $222.5 million, or $3.14 per share, and $133.4 million, or $2.10 per share, respectively. At December 31, 2025, we had $171.8 million of cash and short-term investments. We had $87.9 million in aggregate principal amount of debt at December 31, 2025, reflecting a decrease of $77.1 million, or 47%, compared to $164.9 million in aggregate principal amount of debt at December 31, 2024.

$RCKT event soon, only call/put

$OUST getting close to turnaround eps Ouster Q4 EPS $(0.06) Beats $(0.35) Estimate, Sales $62.178M Beat $41.100M Estimate / Ouster Sees Q1 Sales $45.000M-$48.000M vs $42.933M Est

$GAP